

Contents lists available at ScienceDirect

Seizure

journal homepage: www.elsevier.com/locate/yseiz

Erratum

Erratum to “Add-on treatment with pregabalin for partial seizures with or without generalisation: Pooled data analysis of four randomised placebo-controlled trials”

[Seizure: European Journal of Epilepsy 18 (2009) 184–192]

Antonio Gil-Nagel ^{a,*}, Gaetano Zaccara ^{b,1}, Francesca Baldinetti ^c, Teresa Leon ^c

^a *Epilepsy Program, Neurology Department, Ruber International Hospital, La Maso 38, 28034 Madrid, Spain*

^b *Unita Operativa di Neurologia, Ospedale S.M. Nuova, Piazza S.M. Nuova 1, 50122 Firenze, Italy*

^c *Pfizer Global Pharmaceuticals, 235 East 42nd Street, New York, NY, USA*

In Fig. 1 of the above listed article, asterisks (indicating a significant difference vs. placebo) were inadvertently omitted for the 150 mg/day pregabalin dose. The corrected figure has these asterisks replaced. The *p*-value included on the figure was also corrected (from $p < 0.0001$ to $p \leq 0.001$).

In addition, the figure legend and the Results text report the incorrect *p*-value which appeared on the original figure. Please note the corrections below:

Original text: In the pooled data analysis, significant reductions in seizure frequency were demonstrated for all pregabalin doses studied vs. placebo (Fig. 1), with a positive linear dose–

response relationship ($p < 0.0001$; based on the main ANOVA model).

Corrected text: In the pooled data analysis, significant reductions in seizure frequency were demonstrated for all pregabalin doses studied vs. placebo (Fig. 1), with a positive linear dose–response relationship ($p \leq 0.001$; based on the main ANOVA model).

Original legend: Fig. 1. Percentages reduction in seizure frequency across all treatment groups; * $p < 0.0001$ vs. placebo.

Corrected legend: Fig. 1. Percentages reduction in seizure frequency across all treatment groups; ** $p \leq 0.001$ vs. placebo.

DOI of original article: [10.1016/j.seizure.2008.09.004](https://doi.org/10.1016/j.seizure.2008.09.004)

* Corresponding author. Tel.: +34 913 875 250; fax: +34 913 875 333.

E-mail addresses: agnagel@ya.com (A. Gil-Nagel), gaetano.zaccara@asf.toscana.it (G. Zaccara), teresa.leon@pfizer.com (T. Leon).

¹ Tel.: +39 055 275 8894; fax: +39 055 275 8291.